GEDSA Releases Conclusive Position Statement August 2016
As a summary of previous Position Statements, GEDSA re-emphasizes recommendations including:
“Performance testing conducted by an accredited third party lab and usability studies conducted throughout the world confirm the ENFit LDT syringe when used as instructed:
- Delivers an accurate dose substantially equivalent with current male orientated enteral/oral syringes.
- Outperforms existing female (reverse) orientated syringes.
- Fits into current practice and maintains compatibility with other ENFit devices”
Furthermore, the August GEDSA Position Statement recommends:
“GEDSA and its supporting organizations including the Joint Commission, ISMP, ASHP, ASPEN, NHS, and EPSG encourage manufacturers to introduce enteral devices with ENFit connectors, and healthcare facilities to:
- Adopt feeding systems with ENFit connectors as soon as possible.
- Use ENFit LDT syringes to ensure accurate dose delivery of small volumes.
- Work with your supplier representative and distributor network to understand their specific timing and product availability for transition.
- Confirm syringe suppliers have adequate supplies of standard and LDT ENFit syringes before converting to ENFit feeding tubes”
A new and significant recommendation is included by GEDSA:
“In order to obtain the requisite dose accuracy, manufacturers of ENFit LDT syringes should specify in their instructions for use and labeling that the syringe user should remove fluid that lies outside of the fluid path. The area between the male lumen and the outer ring (the “moat”) is not part of the fluid path and should be free of fluid. For settings that require highly accurate low volume doses, an ENFit LDT Syringe is recommended. The ENFit LDT syringe tip design satisfies the performance expectations for dose accuracy, dead space, and tolerance on graduated capacity.”
NeoMed’s innovative products include DoseMate, an ergonomic tip, which prevents fluid accumulation in the moat during direct oral administration.